|

A Study of EP0031 in Patients With Advanced RET-altered Malignancies

RECRUITINGPhase 1/2Sponsored by Ellipses Pharma
Actively Recruiting
PhasePhase 1/2
SponsorEllipses Pharma
Started2022-09-30
Est. completion2026-12
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations18 sites

Summary

The aim of this study is to assess the safety, side effects and effectiveness of EP0031 in patients with advanced RET-altered malignancies (NSCLC)

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

Applicable to all patients:

1. Must be ≥18 years of age, with documented RET-altered cancers
2. Patients should be well informed and consented about alternative treatment options including approved RET-targeted therapies
3. ECOG performance status of 0 or 1 and life expectancy \>3 months at screening
4. Ability to understand and provide written informed consent and able to participate in all required evaluations and procedures
5. Additional cohort specific criteria apply

Exclusion Criteria:

Patients with any of the following will not be included in the study:

1. Any known major driver gene alterations other than RET.
2. Spinal cord compression or brain metastases. Patients with stable brain metastases can be enrolled.
3. Active infection requiring systemic antibiotic, antifungal, or antiviral medication
4. Severe or uncontrolled medical condition or psychiatric condition
5. Chronic glomerulonephritis or renal transplant
6. Patients with active hepatitis B infection or active hepatitis C
7. Patients with active HIV infection. Patients living with HIV may be eligible if they have adequate CD4+ T-cell count and no history of AIDS-defining opportunistic infections in the past 12 months
8. Receipt of any strong inhibitor or inducer of CYP3A4
9. Impaired hepatic or renal function, inadequate bone marrow reserve or organ function
10. Any clinically important abnormalities in rhythm, conduction, or morphology on resting ECG or any factor that increases the risk of QTc prolongation or of arrhythmic events , or congestive heart failure Grade II-IV according to the New York Heart Association, myocardial infarction, or unstable angina within the previous 6 months
11. Uncontrolled hypertension
12. Corneal ulceration at screening

Conditions3

Advanced Solid TumorCancerNSCLC

Locations18 sites

David Geffen School of Medicine at UCLA
Los Angeles, California, 90095
Andrew Gianoukakis, MDagianoukakis@lundquist.org
Stanford University
Stanford, California, 94305
Emmanuel Ugwueugwu@stanford.edu
Georgetown University
Washington D.C., District of Columbia, 20057
Florida Cancer Specialist
Fort Myers, Florida, 33908
Judy Wang, MDjswang@flcancer.com
RUSH University Medical Center
Chicago, Illinois, 60612

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.